Tyra Biosciences, Inc. (NASDAQ:TYRA) is Sio Capital Management LLC’s 8th Largest Position

Sio Capital Management LLC reduced its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 33.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 400,870 shares of the company’s stock after selling 199,424 shares during the quarter. Tyra Biosciences accounts for 3.7% of Sio Capital Management LLC’s investment portfolio, making the stock its 8th largest position. Sio Capital Management LLC owned 0.79% of Tyra Biosciences worth $9,424,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Walleye Capital LLC grew its position in Tyra Biosciences by 306.5% in the 3rd quarter. Walleye Capital LLC now owns 126,597 shares of the company’s stock valued at $2,976,000 after acquiring an additional 95,451 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Tyra Biosciences during the 3rd quarter worth approximately $593,000. Ally Bridge Group NY LLC lifted its holdings in Tyra Biosciences by 2.0% during the 3rd quarter. Ally Bridge Group NY LLC now owns 270,075 shares of the company’s stock worth $6,349,000 after buying an additional 5,415 shares in the last quarter. FMR LLC grew its stake in shares of Tyra Biosciences by 0.8% in the third quarter. FMR LLC now owns 3,372,850 shares of the company’s stock worth $79,296,000 after acquiring an additional 26,187 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Tyra Biosciences in the third quarter valued at $333,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Insiders Place Their Bets

In related news, Director Nina S. Kjellson sold 11,078 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $16.17, for a total transaction of $179,131.26. Following the completion of the transaction, the director now directly owns 472,207 shares in the company, valued at $7,635,587.19. The trade was a 2.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Todd Harris sold 19,084 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $27.90, for a total value of $532,443.60. Following the completion of the sale, the chief executive officer now directly owns 1,355,927 shares in the company, valued at approximately $37,830,363.30. The trade was a 1.39 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 101,050 shares of company stock worth $2,235,492. Company insiders own 15.40% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on TYRA. HC Wainwright cut their price target on Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, November 11th. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their target price for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Oppenheimer lifted their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. Piper Sandler began coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They set an “overweight” rating and a $33.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a research report on Friday, October 25th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tyra Biosciences currently has an average rating of “Buy” and an average price target of $31.00.

Tyra Biosciences Stock Up 1.8 %

NASDAQ:TYRA opened at $16.00 on Friday. Tyra Biosciences, Inc. has a 52-week low of $10.60 and a 52-week high of $29.60. The stock’s 50 day moving average price is $20.27 and its 200 day moving average price is $19.82. The company has a market capitalization of $809.60 million, a PE ratio of -9.94 and a beta of 1.08.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, sell-side analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.